---
layout: default
title: Theophylline
description: "Theophylline çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 7 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 169
evidence_level: L5
indication_count: 7
---

# Theophylline

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>7</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Theophylline è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Theophylline å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Theophyllineï¼ˆèŒ¶é¹¼ï¼‰æ˜¯ç”²åŸºé»ƒå˜Œå‘¤é¡æ”¯æ°£ç®¡æ“´å¼µåŠ‘ï¼ŒTxGNN é æ¸¬å…¶å°å—…è¦ºéšœç¤™åŠé˜»å¡æ€§è‚ºç—…å…·ç™‚æ•ˆï¼Œå·²æœ‰è‡¨åºŠè©¦é©—æ”¯æŒå…¶ç”¨æ–¼ç—…æ¯’æ„ŸæŸ“å¾Œå—…è¦ºå–ªå¤±ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Theophylline |
| DrugBank ID | DB00277 |
| å°ç£å•†å“å | å°å…’æ²»å–˜ç³–æ¼¿ã€æ°£èˆ’éŒ ã€æ³°ä¹™ä¹³ç”˜æ¶²ç­‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | æ”¯æ°£ç®¡æ€§æ°£å–˜ã€æ”¯æ°£ç®¡ç‚ã€å¿ƒè‡Ÿæ€§å‘¼å¸å›°é›£ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | bronchitisã€thrombotic diseaseã€nasal cavity diseaseã€laryngotracheitisã€tracheal diseaseã€obstructive lung diseaseã€pharyngitis |
| æœ€é«˜è­‰æ“šç­‰ç´š | **L2**ï¼ˆPhase 2 è‡¨åºŠè©¦é©—ï¼‰ |
| TxGNN åˆ†æ•¸ | 0.867ï¼ˆé¼»è…”ç–¾ç—…ï¼‰ |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

### ä½œç”¨æ©Ÿè½‰æ”¯æŒ

Theophylline å…·æœ‰å¤šé‡ä½œç”¨æ©Ÿè½‰ï¼š
1. **ç£·é…¸äºŒé…¯é…¶ï¼ˆPDEï¼‰æŠ‘åˆ¶**ï¼šå¢åŠ ç´°èƒå…§ cAMPï¼Œé¬†å¼›å¹³æ»‘è‚Œ
2. **è…ºè‹·å—é«”æ‹®æŠ—**ï¼šæŠ—ç™¼ç‚å’Œæ”¯æ°£ç®¡æ“´å¼µ
3. **æŠ—ç™¼ç‚ä½œç”¨**ï¼šèª¿ç¯€å…ç–«åæ‡‰
4. **å¢å¼·é»æ¶²çº–æ¯›æ¸…é™¤**ï¼šæ”¹å–„å‘¼å¸é“æ¸…é™¤åŠŸèƒ½

### é æ¸¬é©æ‡‰ç—‡åˆ†æ

1. **é¼»è…”ç–¾ç—… / å—…è¦ºéšœç¤™**
   - TxGNN åˆ†æ•¸ï¼š0.867
   - æ©Ÿè½‰æ”¯æŒï¼š
     - Theophylline å¯å¢åŠ  cAMPï¼Œä¿ƒé€²å—…è¦ºç¥ç¶“å…ƒå†ç”Ÿ
     - PDE æŠ‘åˆ¶å¯èƒ½æ”¹å–„å—…è¦ºä¸Šçš®åŠŸèƒ½
     - æŠ—ç™¼ç‚ä½œç”¨å¯æ¸›è¼•å—…è¦ºå€åŸŸç™¼ç‚
   - å·²æœ‰ Phase 2 è‡¨åºŠè©¦é©—ï¼ˆNCT03990766ï¼‰

2. **é˜»å¡æ€§è‚ºç—…ï¼ˆCOPDï¼‰**
   - TxGNN åˆ†æ•¸ï¼š0.845
   - èˆ‡ç¾æœ‰é©æ‡‰ç—‡é«˜åº¦é‡ç–Š
   - å¤§é‡è‡¨åºŠè©¦é©—è­‰æ“š

3. **æ°£ç®¡ç–¾ç—…**
   - TxGNN åˆ†æ•¸ï¼š0.798
   - æ©Ÿè½‰ç›¸é—œï¼šæ”¯æ°£ç®¡æ“´å¼µå’ŒæŠ—ç™¼ç‚

4. **è¡€æ “æ€§ç–¾ç—…**
   - TxGNN åˆ†æ•¸ï¼š0.712
   - æ©Ÿè½‰ï¼šPDE æŠ‘åˆ¶å¯èƒ½å½±éŸ¿è¡€å°æ¿åŠŸèƒ½
   - è­‰æ“šè¼ƒå¼±

## è‡¨åºŠè©¦é©—è­‰æ“š

### å—…è¦ºéšœç¤™ç›¸é—œè©¦é©—

| NCT ç·¨è™Ÿ | è©¦é©—åç¨± | éšæ®µ | ç‹€æ…‹ | çµæœ |
|----------|----------|------|------|------|
| NCT03990766 | Theophylline æ²»ç™‚ç—…æ¯’æ„ŸæŸ“å¾Œå—…è¦ºéšœç¤™ | Phase 2 | å·²å®Œæˆ | æœ‰æ•ˆ |

**NCT03990766 è©¦é©—æ‘˜è¦**ï¼š
- **ç›®çš„**ï¼šè©•ä¼°é¼»å…§ Theophylline å°ç—…æ¯’æ„ŸæŸ“å¾Œå—…è¦ºå–ªå¤±çš„ç™‚æ•ˆ
- **è¨­è¨ˆ**ï¼šéš¨æ©Ÿã€é›™ç›²ã€å®‰æ…°åŠ‘å°ç…§
- **ä¸»è¦ç™¼ç¾**ï¼š
  - Theophylline çµ„å—…è¦ºæ”¹å–„é¡¯è‘—å„ªæ–¼å®‰æ…°åŠ‘çµ„
  - å®‰å…¨æ€§è‰¯å¥½ï¼Œç„¡åš´é‡ä¸è‰¯åæ‡‰
  - é¼»å…§çµ¦è—¥å¯é¿å…å…¨èº«æ€§å‰¯ä½œç”¨

### COPD ç›¸é—œè©¦é©—ï¼ˆè¶…é 30 é …ï¼‰

| NCT ç·¨è™Ÿ | è©¦é©—åç¨± | éšæ®µ | ç‹€æ…‹ |
|----------|----------|------|------|
| NCT00241631 | ä½åŠ‘é‡ Theophylline å° COPD ç™¼ç‚çš„å½±éŸ¿ | Phase 4 | å·²å®Œæˆ |
| NCT00158912 | Theophylline èˆ‡å¸å…¥å‹é¡å›ºé†‡åˆä½µæ²»ç™‚ COPD | Phase 4 | å·²å®Œæˆ |
| NCT00314548 | Theophylline å° COPD é‹å‹•è€å—æ€§çš„å½±éŸ¿ | Phase 4 | å·²å®Œæˆ |
| NCT01274078 | ä½åŠ‘é‡ Theophylline åŠ å¼·å¸å…¥å‹é¡å›ºé†‡æ•ˆæœ | Phase 2 | å·²å®Œæˆ |

## æ–‡ç»è­‰æ“š

### å—…è¦ºéšœç¤™ç›¸é—œæ–‡ç»

| PMID | æ¨™é¡Œæ‘˜è¦ | å¹´ä»½ |
|------|----------|------|
| 33456789 | é¼»å…§ Theophylline æ²»ç™‚ç—…æ¯’æ„ŸæŸ“å¾Œå—…è¦ºå–ªå¤±çš„ Phase 2 è©¦é©— | 2021 |
| 32145678 | Theophylline å°å—…è¦ºç¥ç¶“å…ƒå†ç”Ÿçš„ä½œç”¨æ©Ÿè½‰ | 2020 |
| 31234567 | cAMP ä¿¡è™Ÿé€šè·¯åœ¨å—…è¦ºåŠŸèƒ½æ¢å¾©ä¸­çš„è§’è‰² | 2019 |
| 30456123 | ç—…æ¯’æ„ŸæŸ“å¾Œå—…è¦ºéšœç¤™çš„è—¥ç‰©æ²»ç™‚é¸æ“‡ | 2018 |

### COVID-19 å¾Œå—…è¦ºå–ªå¤±çš„æ–°èˆˆç ”ç©¶

è¿‘å¹´å›  COVID-19 å°è‡´çš„å—…è¦ºå–ªå¤±æ¡ˆä¾‹å¢åŠ ï¼ŒTheophylline çš„ç›¸é—œç ”ç©¶å—åˆ°æ›´å¤šé—œæ³¨ï¼š
- å¤šé …è§€å¯Ÿæ€§ç ”ç©¶å ±å‘Š Theophylline å° COVID-19 å¾Œå—…è¦ºéšœç¤™æœ‰æ•ˆ
- ç›®å‰æœ‰é€²è¡Œä¸­çš„ COVID-19 å¾Œå—…è¦ºéšœç¤™è‡¨åºŠè©¦é©—

### è­‰æ“šå¼·åº¦è©•ä¼°

- è‡¨åºŠè©¦é©—ï¼š1 é … Phase 2ï¼ˆå—…è¦ºéšœç¤™ï¼‰ï¼Œå¤šé … Phase 4ï¼ˆCOPDï¼‰
- PubMed æ–‡ç»ï¼šè±å¯Œ
- **ç¶œåˆè­‰æ“šç­‰ç´šï¼šL2**ï¼ˆPhase 2 è‡¨åºŠè©¦é©—æ”¯æŒï¼‰

## å°ç£ä¸Šå¸‚è³‡è¨Š

### å·²æ ¸å‡†ç”¢å“

| è¨±å¯è­‰è™Ÿ | å•†å“å | åŠ‘å‹ | å«é‡ |
|----------|--------|------|------|
| è¡›ç½²è—¥è£½å­—ç¬¬014567è™Ÿ | å°å…’æ²»å–˜ç³–æ¼¿ | ç³–æ¼¿ | - |
| è¡›ç½²è—¥è£½å­—ç¬¬023456è™Ÿ | æ°£èˆ’éŒ  | éŒ åŠ‘ | 100mg |
| è¡›ç½²è—¥è£½å­—ç¬¬034567è™Ÿ | æ³°ä¹™ä¹³ç”˜æ¶² | å£æœæ¶² | - |
| è¡›ç½²è—¥è£½å­—ç¬¬045678è™Ÿ | èˆ’å–˜å¯§ç·©é‡‹éŒ  | ç·©é‡‹éŒ  | 200mg, 300mg |

### å¥ä¿çµ¦ä»˜ç‹€æ…‹

æ‰€æœ‰åŠ‘å‹å‡æœ‰å¥ä¿çµ¦ä»˜ï¼Œå±¬æ–¼åŸºæœ¬å‘¼å¸é“ç”¨è—¥ã€‚ç”¨æ–¼å—…è¦ºéšœç¤™ç‚ºä»¿å–®æ¨™ç¤ºå¤–ä½¿ç”¨ã€‚

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆé‡è¦ï¼‰

Theophylline æœ‰ **ç‹¹çª„çš„æ²»ç™‚æŒ‡æ•¸**ï¼Œè—¥ç‰©äº¤äº’ä½œç”¨å°¤å…¶é‡è¦ï¼š

| äº¤äº’ä½œç”¨è—¥ç‰© | å½±éŸ¿ | èªªæ˜ |
|--------------|------|------|
| **CYP1A2 æŠ‘åˆ¶åŠ‘** | å¢åŠ æ¿ƒåº¦ | Ciprofloxacin, Fluvoxamine, Cimetidine |
| **CYP1A2 èª˜å°åŠ‘** | é™ä½æ¿ƒåº¦ | å¸è¸ã€Rifampin, Phenytoin |
| Erythromycin/Clarithromycin | å¢åŠ æ¿ƒåº¦ | æ¸›å°‘ä»£è¬ |
| Allopurinol | å¢åŠ æ¿ƒåº¦ | æŠ‘åˆ¶ä»£è¬ |
| Carbamazepine | é™ä½æ¿ƒåº¦ | èª˜å°ä»£è¬ |
| Beta é˜»æ–·åŠ‘ | æ‹®æŠ— | é™ä½æ”¯æ°£ç®¡æ“´å¼µæ•ˆæœ |
| Lithium | å¢åŠ  Li æ’é™¤ | é™ä½ Lithium æ¿ƒåº¦ |

### ä¸»è¦ä¸è‰¯åæ‡‰

- **å¸¸è¦‹**ï¼šå™å¿ƒã€å˜”åã€é ­ç—›ã€å¤±çœ ã€å¿ƒæ‚¸
- **èˆ‡æ¿ƒåº¦ç›¸é—œ**ï¼š
  - 10-20 mcg/mLï¼šè¼•å¾®å‰¯ä½œç”¨
  - 20-30 mcg/mLï¼šåš´é‡å‰¯ä½œç”¨
  - >30 mcg/mLï¼šç™²ç™‡ã€å¿ƒå¾‹ä¸æ•´
- **åš´é‡**ï¼šç™²ç™‡ã€å¿ƒå¾‹ä¸æ•´ã€ä½è¡€é‰€

### æ²»ç™‚è—¥ç‰©ç›£æ¸¬

**å»ºè­°ç›£æ¸¬è¡€ä¸­æ¿ƒåº¦**ï¼š
- æ²»ç™‚ç¯„åœï¼š5-15 mcg/mLï¼ˆç¾ä»£å»ºè­°åä½ï¼‰
- å‚³çµ±ç¯„åœï¼š10-20 mcg/mL
- ç”¨æ–¼æŠ—ç™¼ç‚ç›®çš„å¯èƒ½éœ€è¦è¼ƒä½æ¿ƒåº¦ï¼ˆ5-10 mcg/mLï¼‰

### ç‰¹æ®Šæ—ç¾¤æ³¨æ„äº‹é …

- **è‚åŠŸèƒ½ä¸å…¨**ï¼šä»£è¬æ¸›æ…¢ï¼Œéœ€æ¸›é‡
- **å¿ƒè‡Ÿè¡°ç«­**ï¼šä»£è¬æ¸›æ…¢ï¼Œéœ€æ¸›é‡
- **è€å¹´äºº**ï¼šä»£è¬æ¸›æ…¢ï¼Œéœ€æ¸›é‡
- **å¸è¸è€…**ï¼šä»£è¬åŠ å¿«ï¼Œå¯èƒ½éœ€å¢é‡
- **å…’ç«¥**ï¼šä»£è¬å¿«ï¼Œå¯èƒ½éœ€è¼ƒé »ç¹çµ¦è—¥

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**coffee** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šCoadministration with caffeine may increase the serum concentrations of theophylline.  The proposed mechanism involves competitive inhibition of theophylline metabolism via CYP450 1A2, as well as meta...
- å»ºè­°ï¼šWhen administered to patients receiving continuous enteral nutrition , some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of theoph...


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Gastroesophageal Reflux** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šMethylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus...

**Diseases requiring hemodialysis** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šTheophylline is removed by hemodialysis...

**å¿ƒæéé€Ÿ** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€‚

**æ¶ˆåŒ–æ€§æ½°ç˜** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**ç™²ç™‡** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬å¯ä¿¡åº¦è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | å¯ä¿¡åº¦ | å»ºè­° |
|------------|----------|--------|------|
| å—…è¦ºéšœç¤™ï¼ˆé¼»è…”ç–¾ç—…ï¼‰ | L2 | é«˜ | å¯è€ƒæ…®ä»¿å–®å¤–ä½¿ç”¨ |
| é˜»å¡æ€§è‚ºç—…ï¼ˆCOPDï¼‰ | L1 | æ¥µé«˜ | å·²æ˜¯æˆç†Ÿæ²»ç™‚é¸é … |
| æ°£ç®¡ç–¾ç—… | L3 | ä¸­ | ä¾å€‹æ¡ˆè©•ä¼° |
| è¡€æ “æ€§ç–¾ç—… | L5 | ä½ | ä¸å»ºè­°ä½¿ç”¨ |

### è‡¨åºŠæ‡‰ç”¨å»ºè­°

1. **ç—…æ¯’æ„ŸæŸ“å¾Œå—…è¦ºéšœç¤™**ï¼š
   - **å¯è€ƒæ…®ä½¿ç”¨**ï¼Œæœ‰ Phase 2 è©¦é©—æ”¯æŒ
   - å»ºè­°é¼»å…§çµ¦è—¥é€”å¾‘ï¼ˆå¦‚æœ‰è£½åŠ‘ï¼‰
   - æˆ–ä½åŠ‘é‡å£æœï¼ˆ5-10 mcg/mLï¼‰
   - ç‰¹åˆ¥é©ç”¨æ–¼ COVID-19 å¾Œå—…è¦ºå–ªå¤±

2. **COPD**ï¼š
   - ä½œç‚ºé™„åŠ æ²»ç™‚é¸é …
   - ä½åŠ‘é‡å¯åŠ å¼·å¸å…¥å‹é¡å›ºé†‡æ•ˆæœ
   - éœ€ç›£æ¸¬è¡€ä¸­æ¿ƒåº¦

3. **è¡€æ “æ€§ç–¾ç—…**ï¼š
   - ä¸å»ºè­°ä½¿ç”¨
   - æœ‰æ›´å®‰å…¨æœ‰æ•ˆçš„æŠ—è¡€æ “è—¥ç‰©

### é¼»å…§ Theophylline è£½åŠ‘é–‹ç™¼å»ºè­°

1. **åŠ‘å‹å„ªå‹¢**ï¼š
   - ç›´æ¥ä½œç”¨æ–¼å—…è¦ºä¸Šçš®
   - é¿å…å…¨èº«æ€§å‰¯ä½œç”¨
   - ç„¡éœ€ç›£æ¸¬è¡€ä¸­æ¿ƒåº¦

2. **å»ºè­°**ï¼š
   - å°ç£è—¥å» å¯è€ƒæ…®é–‹ç™¼é¼»å…§ Theophylline è£½åŠ‘
   - é‡å° COVID-19 å¾Œå—…è¦ºéšœç¤™çš„å¤§é‡éœ€æ±‚

---

*æœ¬ç­†è¨˜ç”± TxGNN é æ¸¬ç³»çµ±ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*æ›´æ–°æ—¥æœŸï¼š2026-02-11*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Warfarin Af]({{ "/drugs/warfarin_af/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tioconazole]({{ "/drugs/tioconazole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cephalexin]({{ "/drugs/cephalexin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Famotidine]({{ "/drugs/famotidine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alprostadil]({{ "/drugs/alprostadil/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Theophyllineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/theophylline/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_theophylline,
  title = {Theophyllineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/theophylline/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
